Sheryl A. McCarthy

Pfizer (United States) — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

13h-index1.8kcitations18works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Phosphodiesterase function and regulation(9), Receptor Mechanisms and Signaling(8), Cholinesterase and Neurodegenerative Diseases(7), Alzheimer's disease research and treatments(3), Neurotransmitter Receptor Influence on Behavior(2)

Publications18 total

Amphetamine sensitization in mice is sufficient to produce both manic- and depressive-related behaviors as well as changes in the functional connectivity of corticolimbic structures
Neuropharmacology·2015· 35 cited
1-[(1-Methyl-1<i>H</i>-imidazol-2-yl)methyl]-4-phenylpiperidines as mGluR2 Positive Allosteric Modulators for the Treatment of Psychosis
Journal of Medicinal Chemistry·2011· 31 citedOpen Access
P1‐146: Transgene dependent, doxycycline‐sensitive cognitive deficits in Tg4510 mutant mouse correlate with insoluble tau epitope accumulation
Alzheimer s & Dementia·2010
P4‐007: Declines in cognitive and sensorimotor function in tg4510 mutant mouse
Alzheimer s & Dementia·2009
3-Benzyl-1,3-oxazolidin-2-ones as mGluR2 positive allosteric modulators: Hit-to lead and lead optimization
Bioorganic & Medicinal Chemistry Letters·2009· 32 citedOpen Access
Preclinical Characterization of Selective Phosphodiesterase 10A Inhibitors: A New Therapeutic Approach to the Treatment of Schizophrenia
Journal of Pharmacology and Experimental Therapeutics·2008· 284 cited
Behavioral characterization of mice deficient in the phosphodiesterase-10A (PDE10A) enzyme on a C57/Bl6N congenic background
Neuropharmacology·2007· 68 cited
Behavioral and neurochemical characterization of mice deficient in the phosphodiesterase-4B (PDE4B) enzyme
Psychopharmacology·2007· 108 cited
Disruption of the neurokinin-3 receptor (NK3) in mice leads to cognitive deficits
Psychopharmacology·2007· 66 cited
Behavioral and neurochemical characterization of mice deficient in the phosphodiesterase-1B (PDE1B) enzyme
Neuropharmacology·2007· 65 cited
Antipsychotic profile of rolipram: efficacy in rats and reduced sensitivity in mice deficient in the phosphodiesterase-4B (PDE4B) enzyme
Psychopharmacology·2007· 88 cited
CP-809,101, a selective 5-HT2C agonist, shows activity in animal models of antipsychotic activity
Neuropharmacology·2006· 131 cited
Inhibition of the striatum-enriched phosphodiesterase PDE10A: A novel approach to the treatment of psychosis
Neuropharmacology·2006· 274 cited
Genetic deletion of the striatum-enriched phosphodiesterase PDE10A: Evidence for altered striatal function
Neuropharmacology·2006· 230 cited
PDE10A knockout mice: Behavioral characterization and effects of papaverine, a PDE10A inhibitor
Schizophrenia Research·2003· 2 cited
The neurochemical and behavioral effects of papaverine in vivo suggest PDE10 inhibition is “antipsychotic”
Schizophrenia Research·2003· 6 cited
Hyperphosphorylated tau and neurofilament and cytoskeletal disruptions in mice overexpressing human p25, an activator of cdk5
Proceedings of the National Academy of Sciences·2000· 335 citedOpen Access
Letters to My Children.
African American Review·1997

Frequent Co-authors

Judith A. Siuciak(13), Douglas S. Chapin(11), John F. Harms(5), Robert D. Williams(4), Frank S. Menniti(4), Christopher J. Schmidt(4), A. Martin(4), Alka Shrikhande(3), Jeffrey L. Stock(3), Patricia A. Seymour(2), John D. McNeish(2), Lorraine A. Lebel(2), F. David Tingley(2), Leslie K. Chambers(2), Christine A. Strick(2), Allen J. Duplantier(2), Ivan Efremov(2), John Candler(2), Angela C. Doran(2), Alan H. Ganong(2)